Companies › Mapi Pharma
2 active drug programs in 5 registered trials: 5 Phase 1; Psychiatry, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cariprazine Dopamine D3 receptor modulator; Dopamine D2 receptor modulator | DRD3, DRD2 | Phase 1 | Schizophrenia | Dec 2026 |
| SG Depot 2 mg GLP-1 receptor agonist | GLP1R | Phase 1 | Diabete Type 2 | May 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07185815 | Cariprazine | Phase 1 | Schizophrenia | Psychiatry | Dec 2026 |
| NCT07563699 | SG Depot 2 mg | Phase 1 | Diabete Type 2 | Metabolic and endocrine | May 2028 |
| NCT07563699 | SG Depot 2 mg | Phase 1 | Diabete Type 2 | Metabolic and endocrine | May 2028 |
| NCT07563699 | SG Depot 2 mg | Phase 1 | Diabete Type 2 | Metabolic and endocrine | May 2028 |
| NCT07563699 | SG Depot 2 mg | Phase 1 | Diabete Type 2 | Metabolic and endocrine | May 2028 |
Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences LB Pharmaceuticals Gedeon Richter Serina Therapeutics Boryung Pharmaceutical Anxo Pharmaceutical AbbVie
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.